This trial is active, not recruiting.

Condition myocardial infarction
Sponsor Vanderbilt University
Start date July 2012
End date December 2017
Trial size 118 participants
Trial identifier NCT01576536, 111760


The aim of the study is to test whether genetic variation in the alpha 2A adrenergic receptor affects diurnal variation in platelet aggregation.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Observational model cohort
Time perspective prospective
Normal healthy volunteers

Primary Outcomes

percentage platelet aggregation
time frame: Within 120minutes of sample collection

Secondary Outcomes

Percentage platelet aggregation to collagen and ADP
time frame: within 120 minutes of sample collection
Percentage platelet aggregation after cold pressor test
time frame: within 120 minutes of sample collection

Eligibility Criteria

Male or female participants from 18 years up to 45 years old.

Inclusion Criteria: - Men and women aged 18 - 45 years inclusive. - Women of the above age will be studied between day 1 and day 14 of a normal menstrual cycle. - Subjects must be willing to give informed consent for the study and able to adhere to the study diet and study procedures. - Subjects and immediate extended family up till grandparents will be Caucasians or African Americans only. - Subjects will be free of any clinically significant disease. - Clinical laboratory test (CBC, blood chemistry) will be within acceptable limits. Exclusion Criteria: - Subjects who have taken any antiplatelet, anticoagulant or procoagulant medicines within the last three weeks preceding the study. - Subjects who have taken medications (including over the counter medications) other than oral contraceptives in the past two weeks. - Subjects who smoke or have smoked in the past 3 months. - Subjects who are presently or were formerly a narcotic addict or alcoholic. - Females with a positive pregnancy test. - Females who are breast feeding.

Additional Information

Official title Genetic Variation in Platelet Aggregation
Principal investigator Michael Stein, MBChB
Description There is a marked diurnal fluctuation in the occurrence of acute myocardial infarction and sudden death, with peak incidences occurring in the early morning. Platelet aggregation has also been shown to increase in the early morning. The investigators will test the hypothesis that ADRA2A genetic variation, specifically haplotype 4, affects platelet aggregation. The investigators will compare diurnal platelet aggregation in haplotype 4 subjects with subjects in the other haplotype families. In addition, the investigators will compare platelet aggregation after the cold pressor test in haplotype 4 with the other haplotype families.
Trial information was received from ClinicalTrials.gov and was last updated in October 2016.
Information provided to ClinicalTrials.gov by Vanderbilt University.